Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (November 2025)
32 slides from Inspiremd's investor presentation, November 2025
Slide 1: InspireMD Poised to Revolutionize the Carotid Intervention Market
InspireMD Poised to Revolutionize the Carotid Intervention Market Nasdaq: NSPR
Slide 2: Disclaimers
Disclaimers Forward-looking statements This presentation contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future f
Slide 3: Executive Leadership Team
Executive Leadership Team Deep industry experience and subject matter expertise Marvin Slosman Shane Gleason Mike Lawless Chief Executive Officer Chief Commercial Officer Chief Financial Officer • 30+ years of medical device • 20+ years of cardiovascular medical • 20+ years of financial leadership e
Slide 4: Now Approved in the U.S. CGuard Prime Carotid Stent System
Now Approved in the U.S. CGuard® Prime Carotid Stent System Ongoing U.S. Commercial Launch, With a Trained and Seasoned Salesforce Driving Adoption A New Level of Stroke Prevention is Here ▪ With over 65,000 patients treated worldwide, we’re ready to elevate embolic prevention for U.S. physicians an
Slide 5: Endovascular Revolution Has Arrived
Endovascular Revolution Has Arrived MicroNetTM covered CGuard® stent platform could become the new gold standard CEREBRAL CORONARY THORACIC/ABDOMINAL PERIPHERAL CAROTID ARTERY ANEURYSMS ARTERY DISEASE AORTIC ANEURYSMS ARTERIAL DISEASE DISEASE5 AWAITING CONVERSION TO ENDO 30% Surgical1 23% Surgical2
Slide 6: $8B Global Market Potential
$8B Global Market Potential ~2.8 million People diagnosed with High Grade Carotid CURRENT UNTREATED GLOBAL MARKET Stenosis (HGCS) $8.0 Billion ~400,000 Global procedures (CEA/CAS/TCAR) annually to treat HGCS (1) ~155,000 CURRENT TREATED US Procedures (CEA/CAS/TCAR) GLOBAL MARKET annually $1.3 Billio
Slide 7: Developer of CGuard Prime Carotid Stent Platform
Developer of CGuard® Prime Carotid Stent Platform Dedicated to advancing the prevention of stroke and treatment of carotid artery disease 7
Slide 8: Transforming the Carotid Intervention Market
Transforming the Carotid Intervention Market CGuard®Carotid Stent Platform CMS Coverage Expanded Proprietary MicroNet Technology Standard Risk and Asymptomatic Reimbursement Highly differentiated platform for treatment of Enables stent-first approach to carotid carotid artery disease and stroke prev
Slide 9: A Picture is Worth a Thousand Words
A Picture is Worth a Thousand Words… VS Surgical Endarterectomy 90% occlusion CGuard® Stent Stenting 9
Slide 10: Carotid Stenting (CAS + TCAR) is on the Rise
Carotid Stenting (CAS + TCAR) is on the Rise CE CS • DRG/CPT data by Facility and HCP 30,000 25,000 • Trailing 12 Quarters through Q4 20,000 2024 15,000 • ~147K annual carotid intervention 10,000 CAS coverage claims TCAR coverage expansion 5,000 expansion • Represents ~90% of procedures (does not in
Slide 11: Market Shift
Market Shift The market has already begun the shift from surgery to stents (procedures and revenue opportunity) 30,000 $210M 2024 30,000 $80M 95,000 40,000 $280M 2027 40,000 $110M 75,000 60,000 $420M 2030 60,000 $160M 45,000 CAS TCAR CEA 11
Slide 12: The CGuard Difference: The Impact of MicroNet Technology
The CGuard® Difference: The Impact of MicroNetTM Technology1 Approximately 2/3 of neurovascular events (stroke, TIA) occur after carotid interventions take place2. Prevention depends on the protection from the stent implanted VS. MicroNet: Advanced Protection Technology MicroNet captures and locks t
Slide 13: Stent Cell Sizes (Mechanism of Action)
Stent Cell Sizes (Mechanism of Action) Area Comparison (mm2) CGuard® RoadSaverTM *165µ 375µ 500µ 1050µ 1900µ Closed cell stent Open cell stent ACCULINK WallStent * Bench test results may not necessarily be indicative of clinical performance. CGuard RoadSaver Gore Close Cell Open cell * Average in le
Slide 14: Long-Term Stent Performance is the Cornerstone of Our Business
Long-Term Stent Performance is the Cornerstone of Our Business Benefits are independent of access method We are positioned to CGuard Prime CAS Tandem capitalize on the ongoing Stroke Transfemoral/ paradigm shift toward a Transradial “stent first” approach and away from surgery CGuard® Prime Tandem T
Slide 15: Scientific Advisory Board (Multidisciplinary KOLs)
Scientific Advisory Board (Multidisciplinary KOLs) Sean Lyden, M.D. Chris Metzger, M.D. Kenneth Rosenfield, M.D. Adnan H. Siddiqui, M.D., Ph.D. Vascular Surgeon Medical Director Interventional Cardiologist Professor, Vice Chairman of Cardiologist the Department of Neurosurgery 15
Slide 16: Unmatched Foundational Data and Evidence
Unmatched Foundational Data and Evidence 16
Slide 17: PMA Trial Design (C-GUARDIANS)
PMA Trial Design (C-GUARDIANS) Prospective, multicenter international single-arm clinical trial Pivotal Study Objective Evaluate the safety and efficacy of the CGuard® Carotid Stent System in the treatment of carotid Primary Endpoints artery stenosis Composite of DSMI through 30 days or ipsilateral
Slide 18: C-GUARDIANS: 30-Day Safety Outcomes
C-GUARDIANS: 30-Day Safety Outcomes 30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 30-day outcomes 30-day DSMI (multiple FDA trials) Intention to Treat Per Protocol1,2 8.30% 30-day DSMI 0.95% (3) 0.63% (2) 5.80% 5.40% 5.20% 5.10% 4.80% Death 0.32% (1) 0.0% (0) 3.50%
Slide 19: C-GUARDIANS: 1 Year Outcomes
C-GUARDIANS: 1 Year Outcomes 365-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials CGUARDIANS 365-day 365-day (multiple FDA trials) Intention to Treat Per Protocol1,2 12.20% 9.60% Primary Endpoint: 30-day 8.90% Death, Stroke, or MI + 1.93% (6) 1.70% (5) Ipsilateral Stroke between 7.
Slide 20: OUS Clinical Data Supporting CGuard Periprocedural Safety
OUS Clinical Data Supporting CGuard® Periprocedural Safety CGuard commercially available in Europe since 2015 (CE Mark) Study Year N DS 30-Day % (n) DSMI 30-Day % (n) CARENET 2015 30 0.0%(0) 0.0%(0) PARADIGM 2016 101 0.0%(0) 0.0%(0) CASANA 2017 82 1.22%(1) 1.22%(1) WISSGOTT I 2017 30 0.0%(0) 0.0%(0)
Slide 21: CARMEN Meta-Analysis (112 Studies, 68K Patients)
CARMEN Meta-Analysis (112 Studies, 68K Patients) 1 30-day and 12-month event rates by stent type (random-effect model) Terumo Event FGS SGS RoadSaver/ Gore (not marketed) CGuard • Improvements from second- Casper generation stents (SGS) 30-day Stroke [%] 3.01 0.60 0.50 2.89 0.54 relative to first-ge
Slide 22: TCAR
TCAR INSPIREMOD
Slide 23: Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow
Transcarotid Arterial Revascularization (TCAR): Direct Carotid Access with Reverse Flow InspireMD Combines SwitchGuard NPS with Best-in-Class CGuard® Implant 1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic
Slide 24: Developing Comprehensive TCAR Solution
Developing Comprehensive TCAR Solution 80cm TCAR Market Opportunity ~3,000 TCAR-trained physicians in the U.S. 1 ~30,000 TCAR procedures (~$210M) performed in the U.S. in 2024, double-digit growth projected 1,2 1 Piper-Sandler model, 05/01/24 2 Piper-Sandler model, 05/01/24 24
Slide 25: Commercial and Corporate
Commercial and Corporate INSPIREMOD
Slide 26: Commercial Traction Progress in the U.S.
Commercial Traction Progress in the U.S. Salesforce Targeting Demand High-powered U.S. commercial team with Leverage claims database to: Strong physician interest paired with a CAS, TCAR, and Neurovascular expertise, • Map carotid stent procedures to the seasoned field team have driven significant p
Slide 27: Roadmap / Milestones
Roadmap / Milestones Key Value Drivers 2025 2026 2027 CGuard® Prime CAS Approval CGuard Prime CAS Market Expansion Potential SwitchGuard NPS Clearance / Launch for CAS Launch (Full TCAR Tool Kit) CGuard Prime indicated stent with U.S Operational Expansion Potential CGuard Prime TCAR Approval Build o
Slide 28: Commercial Footprint
• Active selling in more than 30 countries Commercial Footprint • Over 65,000 systems sold • Average CAS Market share of 25% OUS Signed agreement with Chinese distributor. Working toward distribution FDA PMA approval received in June 2025, Commercial launch in July 2025 Exploring expansion opportuni
Slide 29: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Pending USA 20 7 Rest of World 54 21 InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products IP Counsel: Kligler and Associates, P.A
Slide 30: Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million
Transformational July 2025 PIPE and May 2023 Financing Up To $153.7 Million To advance the company towards successful U.S. commercialization and path to profitability Strong validation from leading July 2025 PIPE Financing of $40.1 million fundamental healthcare investors, with additional participat
Slide 31: Summary Financials
Summary Financials November 3, 2025 NASDAQ Capital Markets NSPR Stock Price $2.29 Average 3 Month Volume 93K Shares Outstanding 42.2M Shares Outstanding with Prefunded Warrants 86.2M Market Capitalization with Prefunded Warrants $197.5M Cash Balance - Sep 30, 2025 $63.4M Debt $0M 31
Slide 32: Nasdaq: NSPR
NASDAQ Nasdaq: = NSPR NSPR